Bayer Shering Pharma AG | Search

Accessibility help Skip to navigation Skip to content Skip to footer

Showing results for Bayer Shering Pharma AG

Sort by

Viewing results 1‒25 of 161

News in-depthBayer AG
Bill Anderson: the Texan wrestling with Bayer’s mountain of pain
...Now based in Leverkusen — whose Bayer-owned football club could win the Bundesliga for the first time in its 120-year history — the executive is drawing on close to 30 years of experience in pharma and biotech...
March 8, 2024
Bayer AG
Bayer CEO calls German group ‘badly broken’ as he holds off split
...He added that the underlying operative problems in the pharma and crop science businesses needed to be addressed without undue job cuts....
March 5, 2024
FT Live
US Pharma and Biotech Summit
Strategies for innovation, pricing and access
Thursday, 16 MayNew York, NY, USA
European companies
Activist investor Jeff Ubben to join Bayer’s supervisory board
...On Thursday, Bayer also announced the early departure of the head of its consumer health unit, Heiko Schipper, who will be replaced by Julio Triana, a senior manager in the group’s pharma division....
February 29, 2024
Bayer AG
Bayer slashes dividend by 95% as it steps up effort to cut debt
...Chief executive Bill Anderson, who joined last year after heading the pharma unit of Swiss rival Roche, said the decision “was not taken lightly” and had “considered investor input.”...
February 19, 2024
Bayer AG
Bayer shares plunge after blood-thinning drug trial halted
...Manns said asundexian was the most promising drug in Bayer’s pharma pipeline. “Without it, the pharma unit is left without sustainable growth.”...
November 20, 2023
Bayer AG
Bayer drug setback adds to new CEO’s problems
...Last month he blasted Bayer’s performance as “unacceptable” and stressed that “all options” were on the table, including splitting the pharma unit from the crop science division....
November 23, 2023
FT Live
Global Pharma and Biotech Summit
Driving life sciences innovation in a disrupted world
Tuesday, 5 NovemberIn-Person & Online Conference
InterviewBayer AG
Bayer chief blames thin drug pipeline on ‘years of under-investment’
...The new chief executive, who has been in the job since the summer and previously ran Roche’s pharma division, disagreed that Bayer’s pharma unit was too small to keep up with larger rivals....
November 26, 2023
LexBayer AG
Bayer: cell therapy is a promising prescription Premium content
...Yet the German conglomerate is making rapid moves in its pharma division....
October 10, 2023
LexBayer AG
Monsanto: Anderson must uproot Bayer’s perennial problem Premium content
...But Bayer’s persistently low multiple against agrochemical and pharma peers underscores the need for change. Anderson wishes to boost pharma, for example, by removing centralised research budgeting....
July 25, 2023
Chemicals
US lawyers keep up pressure on Bayer over Roundup
...Some investors fear that the uncertainty over Roundup’s financial burden could limit Anderson’s room for manoeuvre with regard to a potential separation of Bayer’s crop science business and its pharma unit...
August 7, 2023
InterviewBayer AG
New Bayer chief plans a radically different style to cut bureaucracy
...Two weeks in as CEO, the former head of Roche’s pharma division and ex-chief of its US biotech group Genentech, declined to elaborate on potential structural changes for the multi-headed group....
June 18, 2023
Inside BusinessOlaf Storbeck
Scaling up or selling out: a German take on a corporate dilemma
...As people close to the company insist, a key argument made against selling Bayer’s agricultural business to Monsanto was that the remaining pharma division would then be so small that it could easily become...
July 5, 2023
Bayer AG
New Bayer chief says all options on table after investors push for break-up
...Bayer shares have underperformed ever since and analysts and investors have been pushing to separate the group’s pharma and agrichemical businesses....
April 5, 2023
Bayer AG
Bayer shifts pharma focus away from ‘innovation unfriendly’ Europe
...He added that Bayer was “deprioritising Europe to some degree” and focusing on the US and China, where its pharma division has already established a significant market presence....
January 16, 2023
LexBayer AG
Bayer: activist could revive fortunes of chemical group Premium content
...Even better, Bayer’s pharma unit has more than doubled its peak sales targets to over €12bn....
January 23, 2023
FT Live
Future of the Car
The technology and new business models shaping the next decade in automotive
Tuesday, 7 MaySancroft, Paternoster Square, London EC4M 7DQ, UK
Bayer AG
Bayer chief hits out at US legal system after weedkiller fight
...He defended his record at Bayer, saying he was “very proud” of his seven years in the top job as well as his 35 years in various other roles at the pharma and agrochemicals conglomerate....
February 28, 2023
News in-depthBiotech
Revolutionary Crispr gene editing speeds from lab to treatment room
...Accordingly, big pharma groups like Pfizer, Bayer and Regeneron have taken note, forming partnerships with the pioneers....
August 19, 2022
Bayer AG
Bayer to buy US start-up Vividion for up to $2bn
...“We [often] know there’s a mechanism that causes a disease, but we have no way to attach a drug to that biological mechanism [to treat it],” Bayer’s pharma boss Stefan Oelrich told the Financial Times....
August 5, 2021
Bayer AG
Bayer brushes off looming patent expiries
...Bayer’s head of pharma Stefan Oelrich told the Financial Times earlier this year that the company would soon launch as many as three new drugs with annual sales potential of €1bn after investing heavily...
March 10, 2021
Bayer AG
New Bayer drugs will not bridge revenue gap, says pharma head
...Between them, the two drugs generate more than €6bn in annual sales, more than a third of Bayer’s pharma revenue....
January 13, 2021
Coronavirus treatment
CureVac teams up with Bayer to accelerate development of Covid vaccine
...Stefan Oelrich, the head of Bayer’s pharma division, said: “We are highly committed to making our capabilities and networks available to help end this pandemic.”...
January 7, 2021
LexBiotech
Bayer/gene therapy: blurred visionary Premium content
...It is unlikely AskBio’s knowhow will benefit Bayer’s crop science business. Nor can it be expected to revive the pharma division sufficiently to pave the way for a spin-off....
October 26, 2020
Bayer AG
Bayer spends up to $4bn in gene therapy push
...Bayer is spending up to $4bn for US-based gene therapy pioneer Asklepios BioPharmaceutical as the German group pushes into a fast-growing medical technique in its biggest pharma deal since 2006....
October 26, 2020
LexBayer AG
Bayer: crop blight Premium content
...Bayer’s problem is not just the deterioration in the crop division’s prospects. The pharma arm’s pipeline is also weak. Expect a dividend cut....
October 1, 2020
LexPharmaceuticals sector
Bayer: settling up Premium content
...Big Pharma’s critics argue that legal challenges over the safety of drugs and medical devices reflect a flawed testing system, compromised by a dash for profits....
August 21, 2020

Previous pagePage 1 of 7Next page